JPWO2021180205A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021180205A5 JPWO2021180205A5 JP2022551318A JP2022551318A JPWO2021180205A5 JP WO2021180205 A5 JPWO2021180205 A5 JP WO2021180205A5 JP 2022551318 A JP2022551318 A JP 2022551318A JP 2022551318 A JP2022551318 A JP 2022551318A JP WO2021180205 A5 JPWO2021180205 A5 JP WO2021180205A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pvrig
- nos
- cancer
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010174835.4 | 2020-03-13 | ||
| CN202010174835 | 2020-03-13 | ||
| PCT/CN2021/080470 WO2021180205A1 (zh) | 2020-03-13 | 2021-03-12 | Pvrig结合蛋白及其医药用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516936A JP2023516936A (ja) | 2023-04-21 |
| JPWO2021180205A5 true JPWO2021180205A5 (enrdf_load_stackoverflow) | 2024-04-26 |
| JP7705873B2 JP7705873B2 (ja) | 2025-07-10 |
Family
ID=77672140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551318A Active JP7705873B2 (ja) | 2020-03-13 | 2021-03-12 | Ｐｖｒｉｇ結合タンパク質及びその医薬用途 |
Country Status (8)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117858903A (zh) * | 2021-09-15 | 2024-04-09 | 江苏恒瑞医药股份有限公司 | 一种含抗pvrig/tigit双特异性抗体的药物组合物 |
| TW202327649A (zh) * | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｐｖｒｉｇ／ｔｉｇｉｔ結合蛋白聯合免疫檢查點抑制劑用於治療癌症 |
| CN115819582A (zh) * | 2021-12-24 | 2023-03-21 | 合肥天港免疫药物有限公司 | Pvrig的抗体或其抗原结合片段及其应用 |
| CN116925222A (zh) | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
| CN116925233A (zh) | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
| CN119487079A (zh) * | 2022-06-08 | 2025-02-18 | 山东先声生物制药有限公司 | 一种pvrig/tigit双特异性抗体药物组合物及其用途 |
| WO2024027824A1 (zh) * | 2022-08-05 | 2024-02-08 | 上海君实生物医药科技股份有限公司 | 抗cd112r抗体药物组合物及其用途 |
| AR130172A1 (es) * | 2022-08-10 | 2024-11-13 | Beigene Ltd | Anticuerpos anti-pvrig y métodos de uso |
| CN117957254A (zh) * | 2022-08-31 | 2024-04-30 | 石药集团巨石生物制药有限公司 | 抗pvrig抗体及其应用 |
| CN120187755A (zh) * | 2022-11-10 | 2025-06-20 | 华辉安健（北京）生物科技有限公司 | 抗cd112r抗体及其用途 |
| TW202438106A (zh) * | 2023-03-15 | 2024-10-01 | 大陸商上海邁晉生物醫藥科技有限公司 | 一種含ｐｄ－１／ｐｖｒｉｇ／ｔｉｇｉｔ結合蛋白的醫藥組成物及其醫藥用途 |
| TW202502812A (zh) * | 2023-06-06 | 2025-01-16 | 大陸商上海藥明生物技術有限公司 | 抗pvrig抗體及其用途 |
| WO2025061165A1 (en) * | 2023-09-20 | 2025-03-27 | Laekna Therapeutics Shanghai Co., Ltd. | Antibodies against pvrig or tigit, bispecific antibodies constructed therefrom, methods for their preparation and uses thereof |
| CN120230207A (zh) * | 2023-12-29 | 2025-07-01 | 百奥泰生物制药股份有限公司 | Pvrig结合蛋白、双特异性抗体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| PT656946E (pt) | 1992-08-21 | 2001-12-28 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
| WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8192474B2 (en) * | 2006-09-26 | 2012-06-05 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
| KR101924831B1 (ko) | 2008-04-09 | 2018-12-05 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
| WO2014089113A1 (en) | 2012-12-03 | 2014-06-12 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| HRP20201404T1 (hr) | 2013-07-16 | 2020-11-27 | F. Hoffmann - La Roche Ag | Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita |
| US20170107300A1 (en) | 2014-03-21 | 2017-04-20 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| WO2015174439A1 (ja) | 2014-05-13 | 2015-11-19 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子 |
| IL250583B (en) | 2014-08-19 | 2022-07-01 | Merck Sharp & Dohme | Anti-tigit antibodies |
| SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
| MX374853B (es) * | 2015-02-19 | 2025-03-06 | Compugen Ltd | Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso. |
| EP3259597B1 (en) * | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
| JP6976241B2 (ja) | 2015-08-14 | 2021-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗ｔｉｇｉｔ抗体 |
| CN113956358A (zh) | 2015-09-25 | 2022-01-21 | 豪夫迈·罗氏有限公司 | 抗tigit抗体和使用方法 |
| WO2017066714A1 (en) * | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
| IL264654B2 (en) * | 2016-08-17 | 2023-09-01 | Compugen Ltd | Anti-tigit antibodies, anti-pvrig antibodies and their combinations |
| US11225523B2 (en) * | 2017-06-01 | 2022-01-18 | Compugen Ltd. | Triple combination antibody therapies |
| US11512129B2 (en) | 2017-09-29 | 2022-11-29 | Jiangsu Hengrui Medicine Co., Ltd. | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof |
| EP3802605A1 (en) | 2018-06-01 | 2021-04-14 | Compugen Ltd. | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
| EP4378954A4 (en) * | 2021-07-30 | 2025-05-21 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anti-pvrig/anti-tigit bispecific antibody and application |
| CN117858903A (zh) * | 2021-09-15 | 2024-04-09 | 江苏恒瑞医药股份有限公司 | 一种含抗pvrig/tigit双特异性抗体的药物组合物 |
| EP4403574A1 (en) * | 2021-09-15 | 2024-07-24 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Protein specifically binding to pd-1 and pharmaceutical use thereof |
-
2021
- 2021-03-12 CN CN202180010585.3A patent/CN115003333A/zh active Pending
- 2021-03-12 EP EP21768888.6A patent/EP4119162A4/en active Pending
- 2021-03-12 US US17/905,694 patent/US20240043530A1/en active Pending
- 2021-03-12 TW TW110108958A patent/TWI873311B/zh active
- 2021-03-12 WO PCT/CN2021/080470 patent/WO2021180205A1/zh active Application Filing
- 2021-03-12 KR KR1020227034534A patent/KR20220154140A/ko active Pending
- 2021-03-12 CA CA3170025A patent/CA3170025A1/en active Pending
- 2021-03-12 JP JP2022551318A patent/JP7705873B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110882385B (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| BR112019025188A2 (pt) | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos | |
| CN113347996B (zh) | 治疗肿瘤的联用药物组合物 | |
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| BR112020020826A2 (pt) | Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1 | |
| US20230279096A1 (en) | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer | |
| JP2017537105A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JPWO2021180205A5 (enrdf_load_stackoverflow) | ||
| CN119868579A (zh) | 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用 | |
| TW201520226A (zh) | 泛－ｅｌｒ＋ｃｘｃ趨化因子抗體 | |
| JP2023502585A (ja) | 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害 | |
| CA3110276A1 (en) | Treatment of triple negative breast cancer with targeted tgf-b inhibition | |
| JP5220315B2 (ja) | 抗ＥｐＣＡＭ免疫グロブリン | |
| WO2021160151A1 (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| US20220289825A1 (en) | FUSION PROTEIN TARGETING PD-L1 AND TGF-ß AND USE THEREOF | |
| TW202333786A (zh) | 逆轉treml1誘導之免疫抑制之方法 | |
| CN113244388A (zh) | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 | |
| JP2023509083A (ja) | 腫瘍を予防又は治療するための薬物の調製における抗ｃｄ４７抗体と抗ｃｄ２０抗体の組み合わせの使用 | |
| WO2021180027A1 (zh) | 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法 | |
| TW201716439A (zh) | Ｈｅｒ３抗體 | |
| BR112021010999A2 (pt) | Uso de anticorpo pd-l1 de articulação do complexo de proteína il-15 para tratamento de doenças tumorais | |
| US20170137523A1 (en) | Therapy for gist | |
| EP4516314A1 (en) | Combination of anti-pd-1 antibody and anti-egfr antibody, and use thereof in treatment of head and neck squamous cell carcinoma | |
| CN118613280A (zh) | 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 |